TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05214911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine , Prednisolone
Description: FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
Study: NCT05295810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gas Delivery
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gas Delivery
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gas Delivery
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gas Delivery
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Study: NCT06502002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline infusion
Study: NCT05664672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 1
Description: Mint on!® 2 mg nicotine pouches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 2
Description: Mint on!® 4 mg nicotine pouches
Study: NCT04935333

Intervention type: PROCEDURE
Intervention: Collection of Leiomyoma samples
Description: Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.

Intervention type: PROCEDURE
Intervention: Collection of Leiomyosarcoma samples
Description: Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.

Intervention type: PROCEDURE
Intervention: Collection of control samples
Description: Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
Study: NCT06109155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Study: NCT05664672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 3
Description: Mint on!® 8 mg nicotine pouches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Tobacco
Description: subjects completely stop all tobacco product usage for 7 days
Study: NCT06562192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NNS309
Description: Radioligand imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NNS309
Description: Radioligand therapy
Study: NCT06013579

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Gym Exercise HIIT
Description: Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Gym Exercise CME
Description: Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Coaching Text Messages
Description: The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Coaching Text Messages
Description: The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Control Text Messages
Description: The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Control Text Messages
Description: The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group.
Study: NCT05617014

Intervention type: RADIATION
Intervention: Neuraceq
Description: Amyloid PET imaging with Florbetaben (Neuraceq) injection
Study: NCT06109155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Study: NCT05617014

Intervention type: RADIATION
Intervention: Neuraceq
Description: Amyloid PET imaging with Florbetaben (Neuraceq) injection

Intervention type: RADIATION
Intervention: Neuraceq
Description: Amyloid PET imaging with Florbetaben (Neuraceq) injection

Intervention type: RADIATION
Intervention: Amyvid
Description: Amyloid PET imaging with Amyvid (Florbetapir) injection

Intervention type: RADIATION
Intervention: Amyvid
Description: Amyloid PET imaging with Amyvid (Florbetapir) injection
Study: NCT04671589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Study: NCT05617014

Intervention type: RADIATION
Intervention: Amyvid
Description: Amyloid PET imaging with Amyvid (Florbetapir) injection

Intervention type: RADIATION
Intervention: Tauvid
Description: Tau PET imaging with Tauvid (Flortaucipir) injection

Intervention type: RADIATION
Intervention: Tauvid
Description: Tau PET imaging with Tauvid (Flortaucipir) injection

Intervention type: RADIATION
Intervention: Tauvid
Description: Tau PET imaging with Tauvid (Flortaucipir) injection

Intervention type: RADIATION
Intervention: MK-6240
Description: Tau PET imaging with MK-6240 injection

Intervention type: RADIATION
Intervention: MK-6240
Description: Tau PET imaging with MK-6240 injection

Intervention type: RADIATION
Intervention: MK-6240
Description: Tau PET imaging with MK-6240 injection

Intervention type: RADIATION
Intervention: NAV4694
Description: Amyloid PET imaging with NAV4694 injection

Intervention type: RADIATION
Intervention: NAV4694
Description: Amyloid PET imaging with NAV4694 injection

Intervention type: RADIATION
Intervention: NAV4694
Description: Amyloid PET imaging with NAV4694 injection

Intervention type: RADIATION
Intervention: PI-2620
Description: Tau PET imaging with PI-2620 injection

Intervention type: RADIATION
Intervention: PI-2620
Description: Tau PET imaging with PI-2620 injection
Study: NCT04671589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Injection
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Study: NCT05617014

Intervention type: RADIATION
Intervention: PI-2620
Description: Tau PET imaging with PI-2620 injection
Study: NCT06392009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Study: NCT06019793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS for Chronic Pain
Description: Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
Study: NCT05674461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WhatsApp Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
Study: NCT05169567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05999747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous
Study: NCT06502821

Intervention type: OTHER
Intervention: questtionnaire
Description: questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy

Intervention type: OTHER
Intervention: questtionnaire
Description: questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy

Intervention type: OTHER
Intervention: questtionnaire
Description: questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
Study: NCT01687127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate, calcium salt
Description: Supplement
Study: NCT05665543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLAm app
Description: Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
Study: NCT05206305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation device
Description: Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
Study: NCT04920786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: TB006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline (Placebo)
Description: Sterile saline
Study: NCT06427577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZhenQi FuZheng granules (ShiDaiYangGuang)
Description: 1 bag at a time, twice a day. Oral orally for 4 weeks.
Study: NCT05653388

Intervention type: OTHER
Intervention: Plasma Collection
Description: Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
Study: NCT04928508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-1
Description: OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg
Study: NCT06650982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecha Kucha presentation on MDPRI
Description: Students in the experimental arm will be given training on MDRPI.
Study: NCT04784806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Subjects will consume a 106g patty of cooked ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Subjects will consume a 106g patty of cooked ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Subjects will consume a 106g patty of cooked ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Subjects will consume a 106g patty of cooked ground beef.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground pork
Description: Subjects will consume a 118g patty of cooked ground pork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground pork
Description: Subjects will consume a 118g patty of cooked ground pork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground pork
Description: Subjects will consume a 118g patty of cooked ground pork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground pork
Description: Subjects will consume a 118g patty of cooked ground pork

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: Subjects will consume a 113g patty of cooked tofu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: Subjects will consume a 113g patty of cooked tofu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: Subjects will consume a 113g patty of cooked tofu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: Subjects will consume a 113g patty of cooked tofu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Meat
Description: Subjects will consume a 113g BeyondMeat patty.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Meat
Description: Subjects will consume a 113g BeyondMeat patty.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Meat
Description: Subjects will consume a 113g BeyondMeat patty.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Meat
Description: Subjects will consume a 113g BeyondMeat patty.
Study: NCT05039944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
Study: NCT05629715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA Knee System
Description: The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
Study: NCT06452485

Intervention type: OTHER
Intervention: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.
Description: Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.

Intervention type: OTHER
Intervention: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.
Description: Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
Study: NCT05629715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KneeAlign Computer Assisted Navigation System
Description: The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
Study: NCT06343844

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac imaging to assess left ventricular volumes and function
Description: non-invasive cardiac imaging (echocardiography and MRI)
Study: NCT05366439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Parallel Assignment